je.st
news
Merck Presents First Phase 3 Data in Japanese Patients for Omarigliptin, an Investigational Once-Weekly DPP-4 Inhibitor for Type 2 Diabetes
2014-09-17 15:31:00| Merck.com - Corporate News
Dateline City: WHITEHOUSE STATION, N.J. Omarigliptin significantly reduced HbA1c levels compared to placebo WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of the first data from the Phase 3 clinical development program for omarigliptin, Mercks investigational once-weekly DPP-4 inhibitor for the treatment of type 2 diabetes. In a study in Japanese patients, omarigliptin provided comparable efficacy and tolerability to Mercks once-daily DPP-4 inhibitor JANUVIA (sitagliptin) 50 mg, which is the standard starting dose for sitagliptin in Japan. Language: English Contact: MerckMedia:Pam Eisele, +1 (267) 305-3558Michael Close, +1 (267) 305-1221 or +1 (310) 617-1067orInvestors:Justin Holko, +1 (908) 423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: for
type
data
japanese
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||
|
|||